BRKR Bruker Corporation

Bruker AXS Inc. today announces the promotions of Dr. Frank Burgaezy, Roger Durst, Ph.D. and Bernard Kolodziej to Executive Vice Presidents. The newly appointed Bruker AXS executive management team will be responsible for leading all aspects of the Bruker AXS business, including global sales and marketing, customer support, manufacturing, research and development, operations and financial management. Executive Vice President Dr. Frank Burgaezy now leads the Bruker AXS X-ray diffraction (XRD) business as well as its X-ray fluorescence (XRF) business, and also has global responsibility for marketing at Bruker AXS. Frank is based in Karlsruhe, Germany, and has been the global XRD business manager since September 2002. From 1990 to 2002, Dr. Burgaezy held several scientific, product management and other management positions at Siemens AXS and later Bruker AXS. He studied physics at the University of Stuttgart and at Oregon State University, and he earned his doctorate in physics at the Max-Planck Institute in Stuttgart, Germany. Executive Vice President Roger Durst, Ph.D., now leads the Bruker AXS X-ray single crystal diffraction (SCD) business, and as Chief Technology Officer heads global R&D. Roger is based in Madison, Wisconsin, and previously has managed the same functions as Vice President. Dr. Durst joined Siemens AXS in 1996 as a development scientist and has held several scientific and management positions at Bruker AXS. He received his S.B. in aeronautics and astronautics from the Massachusetts Institute of Technology and his Ph.D. in physics from the University of Texas at Austin. Executive Vice President Bernard Kolodziej now leads the global finance function and European operations, as well as many of the worldwide subsidiaries of Bruker AXS. Bernard is based in Karlsruhe, Germany, and has been Vice President of Finance since April 2004. Previously, Mr. Kolodziej was CFO of European operations since January 1999. Between 1995 and 1999, he held several operations and financial positions within Siemens AXS and later Bruker AXS. Mr. Kolodziej has a Master's degree in business administration, finance and production engineering from the University of Karlsruhe, Germany. Frank Laukien, President and CEO of Bruker BioSciences, said: "We are fortunate to have this team of seasoned and successful executives provide continued and expanded leadership to Bruker AXS. Each of the new Executive Vice Presidents has an outstanding record of accomplishment. I am confident that, together with our established senior management team, they will continue to drive Bruker AXS' growth and financial performance through innovation, successful product development and responsive customer support, as well as operational excellence and margin improvements." ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on x-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.